[go: up one dir, main page]

PE20190517A1 - Preparacion farmaceutica antienvejecimiento - Google Patents

Preparacion farmaceutica antienvejecimiento

Info

Publication number
PE20190517A1
PE20190517A1 PE2019000361A PE2019000361A PE20190517A1 PE 20190517 A1 PE20190517 A1 PE 20190517A1 PE 2019000361 A PE2019000361 A PE 2019000361A PE 2019000361 A PE2019000361 A PE 2019000361A PE 20190517 A1 PE20190517 A1 PE 20190517A1
Authority
PE
Peru
Prior art keywords
liquid
cellular constituents
container
aging
pharmaceutical preparation
Prior art date
Application number
PE2019000361A
Other languages
English (en)
Inventor
Peter Wehling
Julio Reinecke
Original Assignee
Orthogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/001887 external-priority patent/WO2017080668A1/en
Application filed by Orthogen Ag filed Critical Orthogen Ag
Publication of PE20190517A1 publication Critical patent/PE20190517A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)

Abstract

Se refiere a un metodo de preparacion de una composicion antienvejecimiento, el cual comprende: proporcionar un liquido recolectado a partir de un organismo cuyo liquido comprende constituyentes celulares de la sangre, poner en contacto el liquido con un recipiente o medio de contencion. Dicho metodo de preparacion tambien comprende incubar el liquido en el recipiente y opcionalmente eliminar los constituyentes celulares del liquido tras la incubacion. Dicho liquido comprende exosomas que se concentran y opcionalmente eliminar los constituyentes celulares del liquido luego de la concentracion o aislar los exosomas. El metodo tambien comprende la etapa de evitar la incubacion del liquido y la eliminacion de los constituyentes celulares del liquido en contacto con el recipiente o los medios de contencion
PE2019000361A 2016-08-17 2017-05-12 Preparacion farmaceutica antienvejecimiento PE20190517A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16001807 2016-08-17
PCT/EP2016/001887 WO2017080668A1 (en) 2015-11-13 2016-11-14 Pharmaceutical preparation effective in age-related disorders
PCT/EP2016/001888 WO2017080669A1 (en) 2015-11-13 2016-11-14 Pharmaceutical preparation effective in age-related disorders

Publications (1)

Publication Number Publication Date
PE20190517A1 true PE20190517A1 (es) 2019-04-10

Family

ID=61196401

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019000304A PE20190627A1 (es) 2016-08-17 2017-05-11 Preparacion farmaceutica antienvejecimiento
PE2019000361A PE20190517A1 (es) 2016-08-17 2017-05-12 Preparacion farmaceutica antienvejecimiento

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2019000304A PE20190627A1 (es) 2016-08-17 2017-05-11 Preparacion farmaceutica antienvejecimiento

Country Status (21)

Country Link
US (3) US20190290689A1 (es)
EP (4) EP3352769A1 (es)
JP (2) JP2019528281A (es)
KR (2) KR20190049690A (es)
CN (2) CN108348548A (es)
AU (2) AU2017313163B2 (es)
BR (1) BR112019002982A2 (es)
CA (2) CA3033045A1 (es)
CL (2) CL2019000420A1 (es)
CO (2) CO2019001232A2 (es)
CR (2) CR20190139A (es)
EA (2) EA201890841A1 (es)
HK (3) HK1258712A1 (es)
IL (2) IL259007B2 (es)
MA (2) MA42963A (es)
MX (2) MX2019001948A (es)
PE (2) PE20190627A1 (es)
PH (2) PH12019550017A1 (es)
SG (2) SG11201900866YA (es)
TW (2) TW201806606A (es)
WO (3) WO2018033226A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3352769A1 (en) * 2016-08-17 2018-08-01 Orthogen AG Anti-ageing pharmaceutical preparation
CN108841784A (zh) * 2018-07-17 2018-11-20 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种含黄芪甲苷的髓核细胞抗衰老抗凋亡培养基
EP3613424A1 (en) 2018-08-23 2020-02-26 Orthogen AG Novel methods for the production of pharmaceutical agents
EP3903885A4 (en) * 2018-12-27 2022-10-12 Suntory Holdings Limited MEANS FOR INHIBITING THE DEGRADATION OF DENATURED ELASTIN, MEANS FOR PRESERVING NORMAL ELASTIN FIBERS, MEANS FOR INHIBITING THE FORMATION OF AN ELASTIN-ELAFIN COMPOSITE AND SCREENING METHODS FOR SUBSTANCE HAVING AN ELASTIN-ELAFIN COMPOSITE FORMATION INHIBITING ACTIVITY
RU2695264C1 (ru) * 2018-12-27 2019-07-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Хакасский государственный университет им. Н.Ф. Катанова" (ФГБОУ ВО ХГУ им. Н.Ф. Катанова) Способ прогнозирования ускоренного старения организма женщин, основанный на клинических данных о состоянии репродуктивной функции
EP3845566A1 (en) 2019-12-30 2021-07-07 Industrial Technology Research Institute Extracellular vesicle separation method, colloidal particle and preparation method thereof
US12077780B2 (en) 2020-02-14 2024-09-03 Allergan Sales, Llc Conditioned medium from cells cultured under hypoxic conditions and uses thereof
US20250205285A1 (en) * 2022-05-16 2025-06-26 Taiwan Mitochondrion Applied Technology Co., Ltd. Composition for oral damage mitigation, use thereof, and manufacturing method thereof
JP7624256B1 (ja) * 2024-01-26 2025-01-30 万里 坂井 医薬組成物及びその製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0512814A (pt) * 2004-07-01 2008-04-08 Univ Pittsburgh Of The Commmmo exosomas imunossupressivas
DE102006005016A1 (de) * 2006-02-03 2007-08-16 Orthogen Ag Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung
DE202009017772U1 (de) * 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
WO2012076193A1 (de) * 2010-12-10 2012-06-14 Orthogen Ag Kombinationspräparate mit exosomen und corticosteroid
JP6433896B2 (ja) * 2012-08-13 2018-12-05 シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 組織再生のためのエキソソームおよびマイクロリボ核酸
DE102012019088A1 (de) * 2012-09-28 2014-04-03 Orthogen Ag Antibakterielle Arzneimittelpräparate
CN103767985A (zh) * 2012-10-22 2014-05-07 吉林省霍普金斯药物研究院有限责任公司 人源血液或间充质干细胞分泌exosome的制备与应用
KR101784050B1 (ko) * 2014-12-23 2017-10-10 영남대학교 산학협력단 엑소솜을 유효성분으로 함유하는 피부 노화 예방 또는 치료용 약학조성물
CN105477016A (zh) * 2015-11-13 2016-04-13 中国人民解放军第二军医大学 人间充质干细胞来源的外泌体在抗组织纤维化及瘢痕形成中的应用
WO2017080669A1 (en) * 2015-11-13 2017-05-18 Orthogen Ag Pharmaceutical preparation effective in age-related disorders
CN105505854B (zh) * 2016-01-14 2019-07-12 上海市第六人民医院 来源于人尿液细胞的外泌体的获取方法与应用
CN105582576B (zh) * 2016-02-23 2018-08-17 武汉大复生物科技有限公司 提高内皮祖细胞外泌体释放并促进骨缺损修复的生物材料、制备方法及用途
EP3352769A1 (en) * 2016-08-17 2018-08-01 Orthogen AG Anti-ageing pharmaceutical preparation

Also Published As

Publication number Publication date
CO2019001232A2 (es) 2019-02-28
TW201806606A (zh) 2018-03-01
US20190290689A1 (en) 2019-09-26
CA3033899A1 (en) 2018-02-22
WO2018033249A1 (en) 2018-02-22
KR20190046793A (ko) 2019-05-07
AU2017313163B2 (en) 2019-01-03
AU2017313164A1 (en) 2018-05-10
IL259007B1 (en) 2024-03-01
TW201806605A (zh) 2018-03-01
IL259006A (en) 2018-07-31
IL259007B2 (en) 2024-07-01
IL259007A (en) 2018-07-31
HK1259143A1 (zh) 2019-11-29
HK1255619A1 (zh) 2019-08-23
US20210290671A1 (en) 2021-09-23
SG11201901085RA (en) 2019-03-28
CL2019000420A1 (es) 2019-07-05
MA42963A (fr) 2018-08-01
JP2019528281A (ja) 2019-10-10
EP3352769A1 (en) 2018-08-01
BR112019002982A2 (pt) 2019-05-14
WO2018033227A1 (en) 2018-02-22
EA201890841A1 (ru) 2018-09-28
CR20190139A (es) 2019-06-03
AU2017313163A1 (en) 2018-05-10
AU2017313164B2 (en) 2019-01-03
CN108348549A (zh) 2018-07-31
CO2019001265A2 (es) 2019-02-28
BR112019002080A2 (pt) 2019-05-14
WO2018033226A1 (en) 2018-02-22
HK1258712A1 (zh) 2019-11-15
EP3763377A1 (en) 2021-01-13
EP3352770A1 (en) 2018-08-01
SG11201900866YA (en) 2019-02-27
MA42964A (fr) 2018-08-01
MX2019001948A (es) 2019-05-15
PE20190627A1 (es) 2019-04-26
JP2019529357A (ja) 2019-10-17
EP3695845A1 (en) 2020-08-19
PH12019550022A1 (en) 2019-12-02
US20190231816A1 (en) 2019-08-01
MX2019001949A (es) 2019-05-15
EA201890840A1 (ru) 2018-09-28
CR20190091A (es) 2019-05-07
CN108348548A (zh) 2018-07-31
WO2018033227A8 (en) 2019-01-24
PH12019550017A1 (en) 2019-11-04
CL2019000419A1 (es) 2019-07-05
CA3033045A1 (en) 2018-02-22
KR20190049690A (ko) 2019-05-09

Similar Documents

Publication Publication Date Title
PE20190517A1 (es) Preparacion farmaceutica antienvejecimiento
AR080478A1 (es) Metodos para extraer y aislar constituyentes de un material ceculosico
MX2014006904A (es) Método y sistema para determinar la regularidad asociada a los trastornos del ritmo biológico.
EP3345001A4 (en) METHOD AND DEVICES FOR ANALYTICAL COLLECTION, EXTRACTION, CONCENTRATION AND DETECTION FOR CLINICAL APPLICATIONS
CL2014002975A1 (es) Método in vitro para el diagnostico y vigilancia del cáncer, que comprende determinar la razón entre las células treg y otro grupo de células t, seleccionadas de th17, th1 y/o th2.
UY34097A (es) Alineación de anticoagulante de cebado para extracción de sangre.
ITUB20161187A1 (it) Sistema e procedimento per l’associazione dei risultati di analisi eseguite su campioni biologici, in particolare campioni biologici sottoposti ad indagini cliniche, con variabili pre-analitiche a cui detti campioni sono esposti.
AR089900A1 (es) Composiciones y metodos para la recuperacion y/o eliminacion de reactivos de medios porosos
MX2023010385A (es) Tecnicas para analisis comparativo de estrategias de emparejamiento en un sistema de centro de contactos.
MX2016009516A (es) Medicion rapida de la tasa de sedimentacion de los componentes sanguineos formados a partir de pequeños volumenes de muestra.
BR112014026440A2 (pt) assays, methods and apparatus for assessing rna disruption
EA201691094A1 (ru) Получение антител для конъюгации из культур клеток cho
CL2014001150A1 (es) Sistema y metodo donde el sistema particularmente es un dispositivo movil, para la determinacion de la concentracion de solutos en una muestra liquida coloreada, el cual se basa en la obtencion de imagenes de la muestra y de patrones de concentracion conocidos del soluto, y la determinacion de la concentracion de la muestra sobre la base del procesamiento de esas imagenes y los valores de color que las mismas proporcionan
MX2017001979A (es) Metodo y aparato in vitro para analizar el comportamiento de sustancias en ambiente fisiologico simulado.
CO2017003251A2 (es) Método para autentificación de líquido por detección de derivados de flavonoide
MX2016014761A (es) Ensayo para detectar poblaciones celulares linfocitos t colaboradores 1 (th1) y linfocitos t colaboradores (th2).
FR2986071B1 (fr) Procede pour pronostiquer,in vitro, dans un echantillon sanguin, la probabilite pour un patient d'evoluer vers une dengue severe
MX377035B (es) Ensayo biológico de peptidoglicanos.
EA201692182A1 (ru) Способ изготовления технологического устройства и технологическое устройство
IT201600069927A1 (it) Metodo per la diagnosi in vitro di carcinoma tiroideo.
UA103347U (ru) Способ выделения метацеркарии трематода paracoenogonimus ovatus
AR107115A1 (es) Una película plástica pintable y su proceso de elaboración
MX2016015789A (es) Deteccion de endosporas mediante el uso de material de recoleccion hidrofobico.
MX2016009623A (es) Agentes moleculares marcados para representar por una imagen el anti-portador de cistina/glutamato.
RU2012108403A (ru) Способ определения степени эндогенной интоксикации у водолазов

Legal Events

Date Code Title Description
FA Abandonment or withdrawal